RxDoctor Payments Data

Tad Scheri, MD

Family Medicine · Pittsburgh, PANPI 1336136373

Payments from drug & device makers

$750in general payments, 2019–2025

Across 32 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$179
  • Pfizer$119
  • AbbVie$96
  • Astellas Pharma US Inc$65
  • Exact Sciences$50
  • GSK$48
  • plus $192 from 7 others

What the payments were for

  • Food & beverage$63885%
  • Education$659%
  • Gifts$476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$750 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$280,033
Medicare patients
566
Services billed
5,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$163,146
JardianceEmpagliflozin127$150,990
XareltoRivaroxaban120$93,272
OzempicSemaglutide61$70,512
NuplazidPimavanserin Tartrate16$35,508
JanuviaSitagliptin Phosphate33$32,363
TrulicityDulaglutide16$22,519
TradjentaLinagliptin13$17,119
MounjaroTirzepatide19$16,762
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,812
MyrbetriqMirabegron11$12,394
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$11,217
Breo ElliptaFluticasone/Vilanterol19$10,936
Janumet XrSitagliptin Phos/Metformin Hcl12$9,018
Atorvastatin Calcium920$8,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$26$173,123151 claims
PfizerEliquis$119$163,146153 claims
Johnson & JohnsonXarelto$31$93,272120 claims
MerckJanuvia, Janumet Xr$37$41,38145 claims
GSKTrelegy Ellipta, Breo Ellipta$48$25,74841 claims
Astellas Pharma US IncMyrbetriq$65$12,39411 claims
AbbVieSynthroid$96$5,76880 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →